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Rheumatoid antibodies are autoantibodies specific for the constant portion of 
IgG.  In  mice  a  number  of mutant  strains  produce  large  quantities  of these 
antibodies  (1,  2).  Normal  mice  produce  little  or  no  rheumatoid  factor  (RF) 1 
under usual conditions,  but can be induced to do so either by injection with B 
cell  mitogens  (3,  4)  or  by multiple  immunizations  with  protein  antigens  (5). 
Lipopolysaccharide (LPS),  for example,  induces a  very strong  RF response in 
immunized mice, possibly because these mice contain a high frequency of B cells 
capable of producing  RF.  The  RF induction  observed using  multiple  antigen 
administration  is probably caused  by immune  complexes, and  data  consistent 
with  the  hypothesis  that  immune  complex-specific  determinants  trigger  the 
response have been presented (6). 
Recent data (7, 8) showing that immune complexes can act as polyclonal B cell 
stimulators in vitro have raised the possibility that a single mechanism of nonspe- 
cific B cell activation may be at work in both immune complex- and LPS-induced 
RF  production.  To  test  this  question  a  protocol  was  developed  to  directly 
stimulate  RF  production  with  immune  complexes.  This  has  made  a  direct 
comparison between the responses to mitogen and immune complexes possible. 
The results suggest that RF production in autoimmune strains of mice could be 
caused by many mechanisms. 
Materials and Methods 
Mouse Strains.  A/J, CBA/J, BALB/cJ (+/+ and nu/nu),  (A/J × BALB/c), and CBA/ 
N mice were 8-14 wk old. 
Immunizations.  In some experiments a double immunization  protocol was used for the 
induction of rheumatoid antibodies.  Primary immunizations  were done with the protein 
antigen ovaibumin (OVA) emulsified  in an equal volume of complete Freund's adjuvant 
(CFA).  Mice  received 0.2  mg of protein  emulsion  in  a  total  volume of 0.2  ml.  For 
secondary immunizations,  30/Lg of protein was suspended in 200 ~1 saline and injected 
intraperitoneally.  Immune complex immunizations  are described in the figure and table 
legends. 
Antigen Preparation.  Limulus polyphemus hemocyanin conjugated with p-azopbenylar- 
i Abbreviations used in this paper:  CFA,  complete  Freund's adjuvant; CRI, cross-reactive  idiotype; 
HGG, human gamma globulin; Lph-Ars, Liraulus polyphemus hemocyanin conjugated with p-azo- 
phenylarsonate; LPS, lipopolysaccharide; MEM, minimal essential medium; OVA, ovalbumin; PBS, 
phosphate-buffered saline; PFC, plaque-forming cell; RF, rheumatoid factor; SRBC, sheep red blood 
cells. 
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sonate was prepared according to a standard procedure (9).  OVA was purchased from 
Sigma Chemical Co., St. Louis, MO. 
Preparation of Target Erythrocytes.  Ars-coupled sheep red  blood cells  (SRBC) were 
prepared as described (10). The final reaction mixture contained 10 mM Ars diazonium 
salt,  2%  (wt/vol) borate-phosphate-buffered saline  (PBS),  pH  8.2,  and  25%  (vol/vol) 
SRBC. After 45 min incubation on ice, the cells were washed sequentially in PBS and 
minimal essential medium (MEM) (Irvine Scientific, Santa Ana, CA). OVA-coupled cells 
were prepared by the chromium chloride method (11).  Briefly, to an equal volume of 
packed, saline-washed SRBC was added 1 vol of 10 mg/ml OVA and 1 vol of 2 mg/ml 
CrCi3.  The mixture was  incubated  10 min at room temperature and washed again in 
saline. Coupled RBC were stored in PBS, 1% dextrose at 4 °C. 
Monoclonal Antibodies.  id77  (G~,x) and 423E2  (Gl,x) are anti-Ars-specific proteins 
from hybridomas isolated in our laboratory. 36-71 (Gl,x), 31-62 (G~a,x), and 45-273 (Gs,~) 
are  Ars-specific monoclonal antibodies  that  were  kindly provided  by Prof.  Marshak- 
Rothstein of Boston University Medical School (12). All of the Ars-specific hybridoma 
proteins were derived from A]J mice, and all except 423E2 bear the major cross-reactive 
anti-Ars idiotype (CRI) of A/J mice (13). All of the above-mentioned anti-Ars hybridoma 
proteins were affinity purified on Lph-Ars- or human gamma globulin (HGG)-Ars-coupled 
Sepharose 4B. 3A4 (GI ,x), a CRI  +, Ars-nonbinding antibody (14), was purified as described 
(14). 
Plaque Inhibition.  3A4 protein was used as an inhibitor in some of the plaque assays. 
Heat-aggregated 3A4 was prepared by incubating a 4 mg]ml solution of 3A4 in PBS for 
5  min  at  65°C.  The resulting suspension  appeared  opalescent.  This preparation  was 
appropriately diluted in MEM and mixed with the other antibody preparations and cells 
before incubation in the plaquing chambers. 
Hemagglutination Assay.  To measure anti-Ig activity of serum samples, hapten-coupled 
SRBC were sensitized with antihapten antibodies of any of the IgG subclasses.  Antibody 
samples to be tested were serially twofold diluted in saline supplemented with 1% bovine 
serum albumin, and 50-/~1 aliquots were placed into 96-well microtiter trays. An equal 
volume of the SRBC solution containing 0.4% hapten-SRBC,  1 /~g/ml monoclonal anti- 
hapten antibody, and 1% dextrose was added to each microtiter well. After mixing, the 
cells were allowed to settle overnight at 4°C. For anti-OVA hemagglutination measure- 
ments, the SRBC solution contained no additional antibody and the cells were coupled 
with OVA. 
Plaque Assay.  We  modified the procedure of Cunningbam  and  Szenberg (15)  for 
detecting RF PFC. All reagents and cells were diluted or prepared in serum-free MEM. 
Equal volumes of 15% (vol]vol) Ars-SRBC, anti-Ars monoclonal antibody at the appro- 
priate  dilution,  and  guinea  pig  serum  (Difco  Laboratories,  Inc.,  Detroit,  MI;  Gibco 
Laboratories; or Colorado Serum Co., Denver, CO) diluted 1:4 as a source of  complement, 
were added to 1 vol of the antibody-forming cell suspension. This mixture was pipetted 
into glass slide chambers, sealed, and incubated at 37 °C for 35-40 rain (longer incubations 
only slightly increased the maximum number, of plaque-forming cells (PFC) detected and 
often led  to a  deterioration in plaque quality, making scoring uncertain).  Slides  were 
scored for plaques  by visualization under  a  stereoscopic dissecting microscope at  7x 
magnification. 40 t~g/ml monoclonal antibody was used for most of the assays, with the 
exception of 36-71, which developed plaques maximally at a concentration of 20 t~g/ml. 
Preparation of F(ab'~ Fragments.  36-71  and  id77  were dialyzed against  0.1  M  Na 
acetate, 0.2 M NaCI, pH 4.5 at room temperature. Crystalline porcine pepsin(Worthing- 
ton Biochemical Corp., Freehold, N  J) was added to each at a final concentration of 100 
/~g/mi and the digestions were allowed to proceed for 18 h ~t 37°C. The solutions were 
neutralized by the addition of concentrated Tris-HCI. Undigested material was removed 
by passage over Sepharose-coupled staphylococcal protein A (Sigma Chemical Co.). Flow- 
through  fractions  were  concentrated  by  dialysis  against  Aquacide  IIA  (Calbiochem- 
Behring Corp., La Jolla, CA) and the concentrated material was redialyzed against PBS 
before use. 
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reduced  by the  addition  of dithiothreitol  to  a  concentration  of  10  mM,  followed by 
incubation for 30 min at 37°C.  Alklyation was achieved by the addition of 1]11  vol of 
0.3 M iodoacetamide in 0.3 M Tris HCI, pH 8.2 and incubation at room temperature in 
the dark for 20 min. Samples were then dialyzed extensively against PBS before use. 
Results 
Double Immunization Protocol for the Induction of Rheumatoid Antibodies.  It was 
previously shown (5) that secondary (but not primary) immunization of mice with 
a variety of soluble protein antigens can result in the production of lai'ge amounts 
of rheumatoid factor-like autoantibodies.  Fig.  1 shows that one property of this 
response is a striking dependence upon antigen dosage. The response peaks at a 
secondary immunization  dose of  11.1  #g,  resulting  in  38,000  anti-IgG1  PFC/ 
spleen.  In  the  group  receiving no  secondary immunization,  autoantibody  pro- 
duction  was not  observed.  In this experiment,  A/J  mice were immunized  with 
OVA in CFA and then boosted 2 mo later with various amounts of soluble OVA. 
After 4 d, splenic anti-IgG1  PFC responses were measured. 
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FIGURE  1.  OVA-primed A/J mice produced anti-lgOl in response to secondary stimulation 
with OVA. Mice were primed by an injection of 200 #g OVA in CFA. After 2 mo, mice were 
injected intraperitoneally  with various amounts of soluble OVA in PBS, Anti-IgG1 splenic 
PFC were determined after 4 d. Each point represents  the mean value determined from a 
pool of three spleens. Background PFC to the irrelevant antigen, Ars-SRBC, were low (320- 
1,320 PFC/spleen) in all groups and did not depend on the dosage of OVA. NEMAZEE  245 
Immune Complexes Directly Induce Rheumatoid Antibody Production.  A protocol 
was developed for induction of rheumatoid antibodies that relies on the direct 
stimulation  of naive  animals  with  exogenously supplied  immune  complexes. 
Table I details an initial experiment using anti-Lph-Ars serum as the source of 
antibody. Mice that were injected with both antiserum and the Lph-Ars protein 
responded with anti-IgG 1 production, detected 4 d later, whereas mice receiving 
either  of these  two  reagents  alone  produced  very low  levels  of rheumatoid 
antibody. The magnitude of the response to IgG1 was large relative to the anti- 
Ars response measured in the same mice. No anti-Ars PFC response was detect- 
able in the group of mice receiving Lph-Ars alone. 
A protocol in which anti-Lph-Ars antibody was delivered intravenously at the 
same  time  as  an  intraperitoneal  injection  of Lph-Ars  was  more  effective in 
inducing an anti-IgG1 response than a mixture of the two given intraperitoneally 
(Table I). In this experiment, as in the one shown in Fig. 1, the ratio of antibody 
to antigen, rather than absolute amounts of the two, seemed important in eliciting 
the response (compare lines 1 and 2 in Table I). Anti-Ars PFC were increased in 
mice injected with anti-Ars serum alone (Table I, group 4) relative to controls 
that received no antibody. This result was not reproducible using monoclonal 
anti-Ars antibody (Table II). 
Immune Complexes  at Equivalence or Antigen Excess Induce Rheumatoid Antibod- 
ies.  To prove directly that it was the anti-Lph-Ars antibody component in the 
serum that  was  important  in  combining with  Lph-Ars  to  induce rheumatoid 
factor, we substituted syngeneic (Ig4a) affinity-purified monoclonal IgG1  anti- 
Ars antibody for anti-Lph-Ars serum in subsequent experiments. Table II shows 
that the monoclonal antibody 36-71  can induce RF-like antibody production in 
TABLE  I 
PFC/spleen* 
Group  Anti-Lph-Ars*  Lph-Ars!  Anti-Ars 
IgM anti-IgG 1 
IgM  IgG 
#l  ug 
1  200 i.v.  30 i.p.  11,980  440  360 
2  100 i.v.  30 i.p.  20,160  40  0 
3  (100 i.p. plus 30 i.p.)  4,000  600  0 
4  100 i.v.  --  120  2,280  640 
5  --  30 i.p.  120  0  0 
6  --  --  680  80  0 
Passively administered antibody to Lph-Ars given along with Lph-Ars induces the produc- 
tion of autoanti-IgG1 in A/J mice. In groups 1 and 2, mice were injected first with antibody, 
then  immediately with antigen.  Group  3  mice received a  single injection containing the 
antibody and antigen, which had been mixed together within t  rain of injection. 
* Mean of duplicate assays using pooled spleen cells from three mice per group. Background 
PFC  against  highly  conjugated  nitroiodophenol-coupled  SRBC  did  not  differ between 
groups (data not shown). 
* The anti-Lph-Ars serum was obtained from A[J mice and  contained 0.6 #g Ars-binding 
capacity per microliter as determined by. immunoprecipitation. 
| Lph-Ars was diluted to 150 #g]ml in PBS and 0.2 ml/mouse was injected alone (groups  1, 
2, and 5) or mixed with serum (group 3). 246  IMMUNE  COMPLEX-INDUCED  AUTOANTIBODY 
TABLE  II 
36-71  Lph-Ars 
Group  (i.v.)*  (i.p.) 
IgM PFC/spleen* 
Anti-IgG1  Anti-Ars 
ug 
1  300  50  4,760  370 
2  600  50  7,466  e  <40 
3  --  50  360  <40 
4  600  --  160  <40 
Monoclonal IgG1 anti-Ars/Lps-Ars complexes induced anti-IgG1 pro- 
duction in BALB/c mice. Mice were immunized 4 d before sacrifice. 
* See Table I. 
* 36-71 was affinity purified over HGG-Ars-coupled  Sepharose 4B, eluted 
with 3 M KSCN, and dialyzed extensively against PBS. The antibody 
was defivered in a total volume of 200 #1 in PBS. 
0 <40 anti-IgG1 PFC/spleen were detected when Ars-SRBC were coated 
with (Fab')2-36-71. 
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FIGURE 2.  Determination of monoclonal IgG 1 anti-Ars/Lph-Ars  ratio that induces maximal 
RF production. BALB/c mice (three per group) were injected intraperitoneally  with 0.2 mi of 
PBS containing various amounts of Lph-Ars. In addition, all mice were injected with 600 #g 
36-71  protein i.v.  PFC were determined 4 d after injection. Anti-Ars and anti-SRBC PFC 
numbered <400 per spleen in all groups (data not shown). IgM anti-IgG1 (0), IgM anti-IgG2a 
(O). 
combination  with  injected  Lph-ars.  Neither  36-71  nor  Lph-Ars alone  had  any 
effect. 
Fig.  2  shows  the  dependence  of the  autoanti-!gG1  response  on  the  (IgG1) 
antibody/antigen  ratio used to immunize  the mice.  A  pattern  similar to that in 
Fig.  1  was  observed.  Mice  received  a  fixed  amount  of 36-71  (IgG1  anti-Ars) 
intravenously and  were  subsequently  injected intraperitoneally with  a  solution 
containing the indicated amounts of Lph-Ars. An antibody/antigen  ratio of 15:1 NEMAZEE  247 
(wt/wt) was found to maximally stimulate production of anti-IgG 1. Fig. 3 shows 
that in quantitative immunoprecipitation studies, using the same 36-71 and Lph- 
Ars preparations  used for the induction of rheumatoid antibodies,  equivalence 
was also reached at a 36-71/Lph-Ars  ratio of 15:1. 
Specificity of Immune Complex-induced  Antibody.  Fig.  4  shows that anti-IgG1 
induced by immunization with immune complexes  is specific for the Fc region 
of the  IgG1.  When  F(ab')2  IgG1  was used to  coat  target  cells,  free  PFC were 
detected.  Heat-aggregated  IgG 1 added at the time of the assay could specifically 
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FIGURE 3.  Quantitative precipitation of Lph-Ars with monoclonal anti-Ars 36-71. Increasing 
amounts of antigen were added to 20 #l Of 3  mg/ml antibody in a  total volume of 52 #l of 
PBS. After incubation overnight at 4°C, precipitates were centrifuged and washed twice in 
cold PBS.  Protein concentrations were determined by dissolving pellets in 700 #1 Lowry C 
buffer (2% NaCO3, 0.1 M NaOH, 0.01% CuSO4.5H20, 0.02% Na citrate), incubating 10 min 
at room temperature, then adding 70 #l of 1 N  Folin-Ciocalteau reagent. After 30 min, the 
absorbance at 750 nm was measured. 
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FIGURE  4.  Inhibition ofanti-IgO l plaques produced by spleen cells from OVA-hyperimmune 
(O) or 36-71/Lph-Ars-immunized (O) mice. Various amounts of heat-aggregated (5 min, 65 o  C 
treated) IgG1 were added to the indicated final concentrations in the plaquing chambers. (A, 
A) Relative amounts of PFC detected using F(ab')l instead of IgGl-coated target cells. 248  IMMUNE  COMPLEX-INDUCED  AUTOANTIBODY 
inhibit the development of plaques specific for intact IgG1. The concentration 
of heat-aggregated IgG 1 needed to inhibit plaques and the Fc specificity of the 
PFC were entirely comparable to the anti-IgG1 PFC found in mice after multiple 
immunizations by protein antigens (5). 
Kinetics  of RF Antibody  Production  in Response  to Complexes.  The kinetics of 
RF PFC production in immune complex-immunized mice were comparable to 
those of antigen-hyperimmunized mice (Fig. 5). The double immunization pro- 
tocol results in maximum PFC responses 3-4 d after the second immunization 
(5), whereas the immune complex immunization resulted in a peak response on 
day 4 postimmunization. This difference is probably determined by the rate of 
equilibration of the intravenously injected antibody in the tissues of immune 
complex-immunized mice. 
As in the case of mice hyperimmunized with antigen, only rheumatoid anti- 
body-forming cells of the IgM isotype were detected in these experiments (data 
not shown). 
CBA/N  Mice  Respond  to  Immune  Complexes and  Produce  Rheumatoid  Anti- 
body.  When mice bearing the xid genetic defect were subjected to the double 
immunization protocol (see Fig. 1), they were capable of normal RF production 
relative to congenic control mice (Table III). Mice expressing the xid phenotype 
respond poorly to a  variety of T  cell-independent (TI-2) antigens (16).  These 
results suggest that the rheumatoid antibody response is clearly not of the TI-2 
type and that it requires T  cell "help" or is a T  cell-independent response of the 
TI-1 type. 
Table IV shows that xid mice can respond to immune complexes and produce 
anti-IgG 1. Once again there appeared to be no requirement for antigen-primed 
lymphocytes for this response. Three of three mice immunized with immune 
complexes responded by producing large amounts of anti-IgG1, while unimmu- 
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FIGURE 5.  Time course of the BALB/c anti-lgG response to immune complex immunization. 
Mice were injected with 0.6 mg 36-71  (IgG1 anti-Ars) i.v. and 50 ttg Lph-Ars i.p. on various 
days before sacrifice. Each point represents the mean value determined from a pool of three 
spleens. Anti-IgG1 (O), anti-IgG2a (O). NEMAZEE 
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Group* 
Anti-IgG  1 PFC/spleen  Anti-OVA serum titer 
CBA  CBA/N  CBA  CBA/N 
No immunization  <20  <20  <2  <2 
Primed but not boosted  280  50  2  s  2  s 
Primed and boosted  2,640  2,100*  2  s  2  o 
xid  mutant  mice  produce rheumatoid antibodies in  response to  secondary 
antigen stimulation.  12-wk-old mice were immunized with 200  #g OVA in 
CFA and boosted 14 d later with 30 #g of OVA in PBS. 
* Two mice per group. 
* >97% of these PFC were Fc specific as shown by their inability to lyse F(ab')r 
IgG 1-coated SRBC. 
TABLE  IV 
Mouse No.  Treatment 
IgM PFC/spleen* 
Anti-IgG1  Anti-Ars 
1  Immune complexes  14,210  160 
(36-71/Lph-Ars) 
2  Immune complexes  10,780  125 
3  Immune complexes  9,640  40 
4  --  <40  <40 
5  --  <40  <40 
6  --  <40  <40 
xid mice made autoanti-IgGl in response to immune complexes. Mice 
used were 4-too-old males of the CBA/N strain. 
* Mean anti-IgG1 PFC/spleen from mice 1-3 was 11,542; of these, <40 
were found to react with target cells coated with F(ab')r36-71. 
nized mice produced no detectable antibody of this specificity. It appears from 
this and other experiments that immune complex immunization effectively elicits 
rheumatoid antibodies from widely different mouse strains. In addition, CBA/N 
mice share the same IgG1 allotype (IgG4a) as that used for the immune complex 
immunization,  and  both  the  anti-IgG1  from  immune  complex-  and  OVA- 
immunized mice were Fc specific, indicating that the response is truly autospecific 
(Tables III and IV). 
Failure of Immune  Complexes to Induce RF-like Antibodies  in Nude Mice.  To 
determine the cellular requirements of the anti-IgG1 response to immune com- 
plexes, we tested the ability of genetically athymic nu/nu  mice to respond to 
complexes. Fig. 6 shows that these mice were unable to respond to the complexes 
by making RF, while control mice consistently responded to stimulation with the 
complexes. Because nu/nu mice are able to mount T  cell-independent antibody 
responses of both the TI-1 and TI-2 types, but cannot mount T  cell-dependent 
responses, this experiment strongly suggests that the rheumatoid antibody re- 
sponse to immune complexes requires thymus-dependent cells. 
In contrast to the results using complexes, nu/nu mice produced large numbers 
of anti-IgG1 in response to the mitogen LPS (Table V), demonstrating that they 
do not lack the B cells needed to produce anti-IgG1  in response to the IgG1/ 250  IMMUNE  COMPLEX-INDUCED  AUTOANTIBODY 
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FIGURE  6.  Anti-IgG1 PFC production by individual +/+ or nu/nu BALB/c mice injected 
with 0.6 mg 36-71  (i.v.) and 50 #g Lph-Ars (i.p.).  Splenic PFC were determined 4 d after 
immunization of animals. Also included are controls in which +/+ BALB/c mice were injected 
with either 36-71  or Lph-Ars alone. The  horizontal bar marks the mean of the indicated 
values. Individual mice (e), or pools of three mice (O) or four mice (O). This figure combines 
data from a number of different experiments. 
TABLE  V 
PFS/spleen 
PFC specificity  nu/nu  +/+ 
LPS  Control  LPS  Control 
Anti-SRBC  520  160  1,480  80 
Anti-IgG1  8,800  <40  16,120  <40 
Anti-IgG2a  720  <40  <40  <40 
Anti-IgG2b  1,600  <40  280  <40 
Anti-IgG3  200  <40  <40  <40 
LPS stimulation of the RF response. Mice received 20 #g of E. coli LPS 
intraperitoneally in PBS 4 d before sacrifice. Control mice were injected 
with PBS alone. Values represent the mean determined from pools of 
three spleens per group. 
antigen  complexes.  The  LPS-inducible levels of anti-IgG1  were  comparable  in 
+/+  and nu/nu BALB/c  mice. 
Immune  Complexes  Trigger  Autoantigen-specific  Rheumatoid  Antibody  Produc- 
tion.  To rule out the possibility that immune complexes themselves could induce 
polyclonal activation of a  type that requires T  cells (such as has been described 
for pokeweed  mitogen  [17]),  I  immunized  mice with  immune  complexes made 
up of Lph-Ars and either IgG1  or IgG2a anti-Ars and examined  the specificities 
of  the  rheumatoid  antibodies  produced  (Table  VI).  The  clear  result  is  that NEMAZEE 
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Mouse strain  Group 
Monoclonal antibody*  IgM PFC/spleen* 
Anti-lgG1  Anti-IgG2a  Anti-Ars  Isotype  (Ig4a)  |  (Ig 1  e) 
BALB/c (Iga)  1  id77 (R + A)  I  IgG2a  <40  5,960 
2  id77  IgG2a  <40  1,320 
3  36-71  IgG 1  7,720  940 
4  423E2  IgG 1  5,540  480 
(BALB/c X A[J)  5  36-71  IgG1  11,780  ~  1,660 
(Iga/Ige)  6  id77 (R + A)  IgG2a  <40  7,200** 
Stimulation of RF production with various types of immune complexes. Mice were immunized 4 
d before sacrifice. 
* All antibody preparations were affinity purified  from ascites over  HGG-Ars-Sepharose 4B 
columns. Each mouse received 0.6 mg of antibody i.v., in a total volume of 200 #1 PBS, along 
with 50 #g Lph-Ars i.p., also in PBS. 
* Mean values determined from four spleens per group. 
| BALB/c mice produced Ig4a and Igla; A/J mice produced Ig4a and Igle. 
I Mice received id77 antibody that was mildly reduced and alkylated to destroy its complement- 
fixing ability. See Materials  and Methods. 
i 580 PFC/spleen were observed with F(ab')r36-7 l-coated target cells (5% of  the value with native 
36-71-coated cells). 
** <40 PFC/spleen were observed with F(ab')rid77-coated  target cells. 
IgG2a-containing complexes induce the production of anti-IgG2a but not anti- 
IgG1, and IgGl-containing complexes induce anti-IgG1  production along with 
much lower levels of anti-IgG2a. 
Effect of Antibody Class and Complement Fixation on the Induction of Rheumatoid 
Antibodies with Immune Complexes.  One group of mice received mildly reduced 
and alkylated id77  (IgG2a  anti-Ars)  along with  Lph-Ars.  This  treatment (18) 
destroys  most  of the  complement-fixing ability of the  antibody but  does  not 
affect the overall structure of the antibody or its hemagglutination titer on Ars- 
coupled RBC (data not shown). As Table VI shows, mice receiving reduced and 
alkylated IgG2a-containing complexes produced over four times as many anti- 
IgG2a PFC as those that were injected with normal IgG2a-containing complexes. 
A second experiment using (A]J x  BALB/c) mice revealed similar results and 
shows that the anti-IgG2a,  much like the anti-IgG1  antibody produced under 
these conditions, is autospecific and is specific for the Fc portion of IgG (Table 
vi). 
Comparison of the Specificities of Immune Complex- and LPS-induced Rheumatoid 
Antibodies.  Both LPS and immune complexes elicit the production of Fc-specific 
anti-IgG 1. Fig. 7 compares the properties of LPS-induced and immune complex- 
induced anti-IgG1. Spleen cells from mice immunized in these two ways were 
used  in  plaque  assays  in  which  target  cells  were  coated  with  either  IgG1  or 
F(ab')2-IgG1.  No specific PFC were detected in either group using the F(ab')2- 
coated cells. Plaques specific for IgG1 could be inhibited by the addition of heat- 
aggregated,  but  not  unaggregated,  IgG1  in  the  plaquing  chambers.  Equal 
amounts of heat-aggregated  IgG1  were  needed  to  inhibit plaques  formed by 
spleen cells from LPS- and immune complex-immunized mice. 252  IMMUNE  COMPLEX-INDUCED  AUTOANTIBODY 
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FIGURE 7.  Inhibition of anti-IgG  1 plaques produced by spleen cells from LPS-treated (open 
symbols) or immue complex-treated (closes symbols) BALB/c mice. Mice were injected 4 d 
before sacrifice with 20 ttg LPS in saline or immune complexes, as described in Table VI. 
Pooled spleens from three mice per group were used. (O, 0) Degree of inhibition with heat- 
aggregated lgG1 as competitor. (A, A) Level of inhibition found when nonaggregated lgG1 
was used. if'l, I) Plaques detected with F(ab')2-1gGl-coated target cells as a percentage of the 
values obtained with IgG 1-coated cells. 
Discussion 
Mice produce rheumatoid autoantibody in  response to  immune complexes 
composed of syngeneic antibody and antigen. It has previously been shown (5) 
that repeated immunization of mice with protein antigens could give rise to RF 
antibody.  In  this  study,  RF  antibody  production was  directly  stimulated  in 
previously unimmunized mice by injection of antigen and specific, syngeneic 
antibody. It was found that the stimulation of RF antibody production by immune 
complexes in this way was Ig isotype specific: complexes composed of antigen 
and IgG 1 antibody elicited anti-IgG 1 while IgG2a-containing complexes elicited 
anti-IgG2a. 
I conclude from these results that the response to immune complexes is not 
due to polyclonal stimulation of B cells. This result differs from those of Morgan 
and Weigle (7, 8) that suggest that immune complexes act as polyclonal activators 
of B cells in vitro. In unpublished experiments I have seen no difference between 
the splenic anti-SRBC and antinitroiodophenyl PFC responses of unimmunized 
and immune complex-immunized mice, although large RF antibody responses 
could be demonstrated in the latter, suggesting that nonspecific B cell activation 
does  not  occur  under  the  in  vivo  experimental  conditions  used.  I  cannot, 
however, completely rule out the possibility that a  relatively small polyclonal 
stimulation occurs along with a much larger specific anti-IgG response in these 
mice. 
I was interested in assessing the T  lymphocyte dependence of the RF response 
to  immune complexes,  because  the  results  of earlier  experiments  involving 
multiple antigen administration suggested that the anti-IgG response is predom- 
inantly of the IgM  class  and includes little or no IgG antibody. This isotype 
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response to immune complexes appears, in fact, to be T cell-dependent, because 
it is blocked in T  lymphocyte-deficient nu/nu mice, but appears to be normal in 
mice bearing the xid mutation, xid mice fail to respond to a number of T  cell- 
independent (TI-2) antigens because of the absence of the Lyb-5  ÷ B cell subpop- 
ulation (16). 
Although T  cells may be required for the RF response, they need not be 
specifically primed  to  the  antigen  or  antibody  that  makes  up  the  immune 
complex. This result differs from those of Van Snick and Coulie (19) that suggest 
that spleen cells from mice previously immunized to the foreign parts of the 
immune complex are required for RF production. The assay system for RF used 
by these workers may not be sensitive enough to detect the levels of RF produced 
in response to primary immunization with immune complexes. I  believe, how- 
ever, that antigen-specific T  cells can probably augment the response because 
the  levels  of RF  production achieved  with  direct  immunization of immune 
complexes never reach  those of mice immunized twice with protein antigen 
following the protocol described. 
These data suggest that the previously reported (1) autoreactive anti-IgG2a 
production of strain 129 mice may be in response to immune complex formation. 
Consistent with this idea are the elevated IgG2a titers of these mice. NZB, MRL/ 
1, and other strains of mice producing rheumatoid antibody also appear to suffer 
from immune complex disease and may make the anti-IgG in response to these 
complexes (2, 20). 
Nude mice and normal mice have B cells capable of producing rheumatoid 
antibody in response to injection with LPS (this study and 21). Because in this 
study nude mice did not respond to immune complexes, I  conclude that two 
independent pathways of rheumatoid antibody production are possible: (a)  T 
cell-independent, polyclonal B cell activation resulting in production of antibody 
specific  for  a  wide  variety  of antigens  in  addition  to  self-IgG.  (b)  T  cell- 
dependent, immune complex-specific, immune responsiveness. 
Despite their differing mechanisms of induction and their cellular require- 
ments, LPS- and immune complex-induced rheumatoid antibody have similar 
binding specificities. Anti-IgG1 produced by spleen cells from LPS- and immune 
complex-injected BALB/c mice proved indistinguishable from one another in 
terms of their abilities to bind heat-aggregated IgG1 in a hemolytic plaque assay 
and in their shared specificities for the Fc portion of IgG, suggesting that a given 
B cell capable of producing RF could be triggered by two different mechanisms. 
The preference for  IgG1  in the rheumatoid antibody response to immune 
complexes caused by hyperimmunization appears to be  due to  three factors. 
First, the precursor frequency of B cells with this specificity, as compared with 
B cells specific for other IgG isotypes, appears to be greater, as judged by LPS- 
stimulatable anti-IgG splenic PFC. This conclusion is supported by the studies of 
Van Snick and Coulie (4)  of hybridomas derived from LPS-stimulated mouse 
spleen cells, showing that  58  of 68 autoanti-IgG-specific hybridoma proteins 
bind IgG1  exclusively. Second, IgG1  is usually produced in somewhat higher 
concentrations than other IgG classes in a number of antibody responses and so 
generally makes up a larger fraction of the IgG component of immune complexes 
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complement may mask the Fc determinants normally seen by the rheumatoid 
antibody-producing cells, as suggested by the fact that complexes which included 
non-complement-fixing IgG2a  were  more  effective  than  complement-fixing 
IgG2a in eliciting a specific anti-IgG2a response. In addition, immune complexes 
that have fixed complement are probably cleared more rapidly by phagocytic 
cells  than  those  that  do  not.  Thus,  complement deficiency or  complement 
consumption due to the presence of very large amounts of complement-fixing 
immune complexes could result in production of rheumatoid antibody specific 
for the Fc portions of complement-fixing IgG isotypes. 
The appearance of roughly equal levels of RF PFC in both nude and normal 
BALB/c mice injected with  LPS suggests that  B  cells  with anti-self antibody 
specificity are  probably  not  expanded  in  nonimmune mice,  due  to  ongoing 
environmental immune complex stimulation. This is because nude mice produce 
much lower levels of IgG than normal mice and should therefore not be able to 
develop IgG-containing immune complexes that would stimulate anti-IgG anti- 
body-specific B cells to the same extent as normal mice. These data are supported 
by Izui et al. (21) who have shown that LPS-induced autoanti-IgG serum levels 
in nu/nu and normal C57BL mice are comparable. These and other studies (22) 
show  that  the  frequency of B  cells  capable  of producing RF  after  mitogen 
stimulation is  very high,  underscoring the importance of testing the role  of 
polyclonal activation in immune complex-induced RF production. 
Summary 
Immunization of mice with a combination of passively administered syngeneic 
IgG (anti-p-azophenylarsonate [anti-Ars]) antibody and a  soluble, multivalent 
form of the antibody's corresponding antigen (Limulus polypheraus hemocyanin 
conjugated with Ars [Lph-Ars]) resulted in specific autoanti-IgG Fc (rheumatoid 
factor) production. The response was rapid and only anti-IgG of the IgM isotype 
is found. Because immunization with either the IgG antibody or the antigen 
alone did not result  in  rheumatoid antibody production, immune complexes 
appear to be the active form of the immunogens. Antibody/antigen ratios that 
resulted in maximal anti-IgG antibody responses were the same as those required 
for peak in vitro immunoprecipitation, i.e., equivalence. Previous exposure of 
the mice to the exogenously supplied antigen was not required for the response. 
The response to immune complexes is specific because mice immunized with 
IgG2a-containing complexes produced autoanti-IgG2a, while mice immunized 
with  IgGl-containing complexes produced anti-lgG1  with  little  reactivity  to 
other IgG isotypes. IgG2a blocked in its complement-fixing capacity was more 
effective in eliciting the anti-IgG2a repsonse than native IgG2a,  suggesting a 
possible role for the complement system in modulating the anti-IgG2a response. 
Induction of rheumatoid factor production by immune complexes could be 
induced in xid mice but not in nu/nu mice, indicating T  lymphocyte dependence 
of the response. In contrast, the B lymphocyte activator lipopolysaccharide was 
able to elicit vigorous rheumatoid factor production in both nu/nu and normal 
mice, demonstrating that nu/nu  mice contain B  cells  capable  of making the 
response.  Rheumatoid antibody produced in  the immune complex- or LPS- NEMAZEE  255 
induced responses is Fc specific and has relatively low affinity for IgG that is not 
bound to antigen. 
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